Skip to main content
SpringerLink
Log in

Induction of Lymphokine-Activated Killer (LAK) Cells Against Human Leukemia Cells

  • Conference paper
Modern Trends in Human Leukemia VIII

Part of the book series: Haematology and Blood Transfusion / Hämatologie und Bluttransfusion ((HAEMATOLOGY,volume 32))

  • 90 Accesses

Abstract

Lymphokine-activated killer (LAK) cells are known to lyse fresh solid tumor cells in vitro [1], and clinical studies suggest that adoptive immunotherapy with LAK cells and interleukin-2 (IL-2) may be a promising approach in the treatment of solid tumors [2, 3]. As only few data are available on the LAK cell system in connection with human leukemia [4, 5], we investigated the induction of LAK cells against human leukemia cells in vitro and studied the augmentation of cytotoxic mechanisms which may be achieved by the combined application of different lymphokines or the coculturing of effector cells with tumor cells.

Supported by the Deutsche Krebshilfe e.V., Bonn (W 19/87/Te 1)

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA (1982) Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823–1841

    Article  PubMed  CAS  Google Scholar 

  2. Rosenberg SA, Lotze MT, Muul LM, Chang AE, Avis FP, Leitman S, Linehan WM, Robertson CN, Lee RE, Rubin JT, Seipp CA, Simpson CG, White DE (1987) A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and in- terleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316: 889–897

    Article  PubMed  CAS  Google Scholar 

  3. West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK (1987) Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med 316: 898–905

    Article  PubMed  CAS  Google Scholar 

  4. Oshimi K, Oshimi Y, Akutsu M, Takei Y, Saito H, Okada M, Mizoguchi H (1986) Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells. Blood 68: 938–948

    PubMed  CAS  Google Scholar 

  5. Lotzovâ E, Savary CA, Herberman RB (1987) Induction of NK cell activity against fresh human leukemia in culture with interleukin 2. J Immunol 138: 2718–2727

    PubMed  Google Scholar 

  6. Ludwig W-D, Bartram CR, Ritter J, Raghavachar A, Hiddemann W, Heil G, Harbott J, Seibt-Jung H, Teichmann JV, Riehm H (1988) Abiguous phenotypes and genotypes in 16 children with acute leukemia as characterized by multi-parameter analysis. Blood 71: 1518–1528

    PubMed  CAS  Google Scholar 

  7. Lotzovâ E, Savary CA, Herberman RB, Dicke KA (1986) Can NK cells play a role in therapy of leukemia? Nat Immun Cell Growth Regul 5: 61–63

    PubMed  Google Scholar 

  8. Belldegrun A, Muul LM, Rosenberg SA (1988) Interleukin-2 expanded tumor-in-filtrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity. Cancer Res 48: 206–214

    PubMed  CAS  Google Scholar 

  9. Itoh K, Shiiba K, Shimizu Y, Suzuki R, Kumagai K (1985) Generation of activated killer (AK) cells by recombinant in- terleukin-2 (rIL-2) in collaboration with interferon-gamma ( IFN-y ). J Immunol 134: 3124–3129

    PubMed  CAS  Google Scholar 

  10. Perussia B, Ramoni C, Anegon I, Cuturi MC, Faust J, Trinchieri G (1987) Preferential proliferation of natural killer cells among peripheral blood mononuclear cells cocultured with B-lymphoblastoid cell lines. Nat Immun Cell Growth Regul 6: 171–188

    PubMed  CAS  Google Scholar 

  11. Phillips JH, Lanier LL (1985) A model for the differentiation of human natural killer cells. Studies on the in vitro activation of Leu-11+ granular lymphocytes with a natural killer-sensitive tumor cell, K 562. J Exp Med 161: 1464–1482

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Hematology and Oncology, Klinikum Steglitz, Free University of Berlin, D-1000, Berlin, Germany

    J. V. Teichmann, W.-D. Ludwig, H. Seibt-Jung, G. Sieber & E. Thiel

Authors
  1. J. V. Teichmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. W.-D. Ludwig
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Seibt-Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. G. Sieber
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. E. Thiel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Medizinische Klinik, Abteilung für klinische Chemie, Universitäts-Krankenhaus Eppendorf, Martinistraße 52, 2000, Hamburg 20, Germany

    Rolf Neth

  2. Laboratory of Tumor Cell Biology, National Cancer Institute, 20892, Bethesda, MD, USA

    Robert C. Gallo

  3. Chester Beatty Laboratories, Leukemia Research Fund Centre, Institute of Cancer Research, Fulham Road, London, SW3 6JB, UK

    Melvyn F. Greaves

  4. Abteilung Pädiatrie II, Universitätskinderklinik und Poliklinik Ulm, Prittwitzstr. 43, 7900, Ulm, Germany

    Gerhard Gaedicke

  5. Universität Ulm, Prittwitzstr. 43, 7900, Ulm, Germany

    Gerhard Gaedicke

  6. Labor für Hautimmunologie, Bioverträglichkeit-Immunologie, Paul-Gerson-Unna-Forschungszentrum, Beiersdorf-AG, Unnastr. 48, 2000, Hamburg 20, Germany

    Sven Gohla

  7. Heinrich-Pette-Institut für Experimentelle Virologie und Immunologie, Martinistr. 52, 2000, Hamburg 20, Germany

    Klaus Mannweiler

  8. Abteilung Hämatologie und Onkologie, Kinderklinik und Poliklinik der Westfälischen Wilhelms-Universität, Albert-Schweitzer-Str. 33, 4400, Münster, Germany

    Jörg Ritter

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Teichmann, J.V., Ludwig, WD., Seibt-Jung, H., Sieber, G., Thiel, E. (1989). Induction of Lymphokine-Activated Killer (LAK) Cells Against Human Leukemia Cells. In: Neth, R., et al. Modern Trends in Human Leukemia VIII. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 32. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74621-5_78

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-74621-5_78

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-50967-7

  • Online ISBN: 978-3-642-74621-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation